title: Early assessment of leukocyte alterations at diagnosis of septic shock.
abstract: A dramatic decrease in circulating lymphocyte number is regularly described after septic shock. However, it is unknown how early this alteration develops after diagnosis of shock and if it remains stable over time. Twenty-one septic shock patients with no comorbidities were included within 2 h after the beginning of vasopressive treatment. Flow cytometry phenotyping of circulating leukocyte subpopulations and quantitative real-time polymerase chain reaction of T-bet, GATA-3, FOXP3, and RORγ mRNA were performed in patients from the diagnosis of shock and every 6 h during the subsequent 48 h. From their admission in the intensive care unit, patients present with major alterations of circulating leukocyte count (leukocytosis, neutrophilia, and major lymphopenia). The numbers of every lymphocyte subpopulations (T, B, and natural killer cells) were diminished. Gene expression analysis of transcription factors specific for TH1, TH2, CD4CD25 regulatory, and TH17 lymphocytes showed a severe decrease in comparison with healthy individuals' values. These alterations remain stable during the first 48 h after inclusion in the protocol despite early and aggressive resuscitation and antibiotherapy administered in patients. At the time of diagnosis of shock and admission in the intensive care unit, septic patients already present with severe lymphopenia involving every lymphocyte subsets including CD4 T-cell subpopulations. No significant variation could be detected within the first 48 h. This should be taken into account in the forthcoming clinical trials testing immunomodulating therapies in septic shock patients.
authors.affiliation: Hospices Civils de Lyon, CRB Sepsis, France.
authors.forename: Fabienne
authors.initials: F
authors.lastname: Venet
authors.forename: Fanny
authors.initials: F
authors.lastname: Davin
authors.forename: Caroline
authors.initials: C
authors.lastname: Guignant
authors.forename: Audrey
authors.initials: A
authors.lastname: Larue
authors.forename: Marie-Angélique
authors.initials: MA
authors.lastname: Cazalis
authors.forename: Romain
authors.initials: R
authors.lastname: Darbon
authors.forename: Caroline
authors.initials: C
authors.lastname: Allombert
authors.forename: Bruno
authors.initials: B
authors.lastname: Mougin
authors.forename: Christophe
authors.initials: C
authors.lastname: Malcus
authors.forename: Françoise
authors.initials: F
authors.lastname: Poitevin-Later
authors.forename: Alain
authors.initials: A
authors.lastname: Lepape
authors.forename: Guillaume
authors.initials: G
authors.lastname: Monneret
mesh_terms: D000368:Aged; D005260:Female; D005434:Flow Cytometry; D051858:Forkhead Transcription Factors / Q000235:genetics; D050990:GATA3 Transcription Factor / Q000235:genetics; D006801:Humans; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000235:genetics; D016133:Polymerase Chain Reaction; D012772:Shock, Septic / Q000175:diagnosis* / Q000378:metabolism*; D020825:T-Box Domain Proteins / Q000235:genetics; D000098815:T-bet Transcription Factor
chemical_list: C418974:FOXP3 protein, human; D051858:Forkhead Transcription Factors; D050990:GATA3 Transcription Factor; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D020825:T-Box Domain Proteins; D000098815:T-bet Transcription Factor